Transport Groups Challenge Trump Cannabis Rescheduling Over Drug Testing

Transportation industry leaders are pushing back against the Trump administration's cannabis rescheduling initiative, citing potential disruptions to existing drug testing frameworks for safety-sensitive positions. The American Trucking Associations spearheads a coalition warning federal officials about unintended consequences for current workplace safety protocols that govern truck drivers, pilots, and transit operators.

The industry concerns center on how rescheduling cannabis from Schedule I could complicate existing Department of Transportation drug testing requirements. Current federal regulations mandate zero-tolerance policies for cannabis use among commercial drivers and aviation personnel, regardless of state-level legalization. Transportation groups argue that rescheduling without clear regulatory guidance could create legal ambiguity around these safety protocols.

This pushback highlights a critical tension in cannabis policy reform between expanding access and maintaining workplace safety standards in federally regulated industries. The transportation sector employs millions of workers subject to strict drug testing requirements, and any policy changes could affect major publicly traded companies including trucking firms and airlines that must comply with federal safety mandates.

The coalition's intervention adds another layer of complexity to federal rescheduling efforts, which cannabis companies have viewed as a catalyst for banking access and tax relief under Section 280E. However, industry-specific regulatory challenges could slow implementation and require additional agency coordination between the DEA, DOT, and FAA to address safety-sensitive employment sectors.

Transportation industry resistance demonstrates how cannabis rescheduling extends beyond traditional cannabis businesses to affect broader economic sectors. The outcome of these discussions could influence the timeline and scope of federal cannabis policy changes, potentially affecting investor expectations around regulatory reform benefits for cannabis operators and ancillary businesses serving federally regulated industries.